The partnership enables global manufacturing of key components for AlphaDirect™, the company’s proprietary Pb212 isolation technology intended to develop novel alpha radioligand therapies.
CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, and INDIANAPOLIS, July 24, 2023 /PRNewswire/ — ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha-ligand therapies (ARTs), and SpectronRx, a leading developer and manufacturer of radiopharmaceuticals, today announced a strategic partnership agreement to support the manufacturing of ARTBIO’s AlphaDirect™ isotope isolation technology components.
As part of the agreement, SpectronRx will be responsible for manufacturing a critical component of ARTBIO’s proprietary AlphaDirect™ technology. AlphaDirect™ is the first system of its kind to offer high purity Pb212 from widely available raw materials. The multi-year agreement covers an initial phase of technology transfer and development, followed by the qualification and release of technical components.
“We have a long history of managing complicated technology projects involving radioactive materials,” said SpectronRx co-founder and CEO John Zehner. “We understand the importance of collaboration for companies developing new technologies to create radioligand therapies. SpectronRx is well equipped and is proud to partner with ARTBIO to develop and supply key components of AlphaDirect™.”
ARTBIO pioneered AlphaDirect™ technology to create a patented and optimized Pb212 isotope isolation technology with unique advantages, including:
SpectronRx will leverage its expertise in handling and producing rare medical radioisotopes such as Ac-225 (actinium-225) and Pb-212, along with its infrastructure for radiopharmaceutical contract development (rCDMO) and radiopharmaceutical contract manufacturing (rCMO). This unique combination and extensive regulatory track record will allow ARTBIO to effectively improve and validate its manufacturing processes to prepare them for FDA and EMA review.
“We are pleased to partner with SpectronRx, a company with extensive experience and capabilities in managing nuclear chemistry projects,” said Emanuele Ostuni, Ph.D., CEO of ARTBIO. “Handling high doses of radioactivity is an extremely complex process, and it was critical that we work with a partner who understood the specific requirements needed and could create a custom solution for our proprietary AlphaDirect™ technology. With SpectronRx’s expertise, we are one step closer to establishing the ARTBIO manufacturing network.”
“ARBIO’s technology has the potential to revolutionize the field of cancer treatment,” added SpectronRx President Anwer Rizvi. “We are thrilled to be a part of your incredible journey.”
About ARTBIO ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ART). ARTBIO’s unique approach selects the optimal alpha-emitting isotope (Pb212) and tumor-specific targets to create highly specific therapies. The company’s AlphaDirect™ technology, the first Pb212 isolation method of its kind, enables a distributed manufacturing approach to the reliable production and delivery of ART. ARTBIO is advancing three pipeline programs with lead program AB001 currently in the first in human trials. ARTBIO builds on a long-standing scientific heritage with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and the Radium Hospital in Norway. For more information, visit www.artbio.com, and follow us on LinkedIn (@artbio-inc) and Twitter (@artbio_inc).
About SpectronRx SpectronRx is a developer and manufacturer of diagnostic and therapeutic radiopharmaceuticals with three distinct specialties: radiopharmaceutical contract development (RCDMO), radiopharmaceutical contract manufacturing (RCMO) and isotope manufacturing. The company performs all scales of development, from initial conjugations to scaling and commercial distribution. It also has the capacity to conduct clinical trials. In addition, SpectronRx’s deep industry knowledge, technical prowess and state-of-the-art facilities allow the company to significantly condense the timeline for bringing new drugs to market, which has the double benefit of saving lives and generating greater profitability for customers.
With a large staff of radiochemists, radiopharmacists, scientists and engineers, dozens of qualified clean rooms and more than 150,000 square feet of production space in Indiana, with additional facilities in Danbury, Connecticut and Europe, SpectronRx now supplies therapeutic and diagnostic radiopharmaceuticals to 29 countries. The company has been inspected by the EMA and the FDA and can produce and purchase any radioisotope in current use, including actinium-225. For more information, visit SpectronRx.com, or follow the company on LinkedIn.
Logo – https://mma.prnewswire.com/media/2106824…
View original content: https://www.prnewswire.com/news-releases/artbio-y-spectronrx-se-unen-para-fabricar-componentes-clave-de-la-tecnologia-alphadirect-de-artbio-301883702.html
